Feb 15 (Reuters) - Peter Steinberger, the founder of OpenClaw, is joining OpenAI, and the open-source bot is becoming a foundation, OpenAI CEO Sam Altman said on Sunday. "Peter Steinberger is joining ...

Sign of the times: An AI agent autonomously wrote and published a personalized attack article against an open-source software maintainer after he rejected its code contribution. It might be the first ...

What happens when you create a social media platform that only AI bots can post to? The answer, it turns out, is both entertaining and concerning. Moltbook is exactly that—a platform where artificial ...

What happens when thousands of AI agents get together online and talk like humans do? That’s what a new social network called Moltbook, designed just for AI bots and not people, aims to find out. And ...

A new website called Moltbook has become the talk of Silicon Valley and a Rorschach test for belief in the state of artificial intelligence. By Cade Metz Reporting from San Francisco Last Wednesday, ...

Humans have left the chat. AI bots now have their very own social network — and they’re ready to delete humanity. A revolutionary new social media platform called Moltbook debuted this week, giving AI ...

It’s the kind of back-and-forth found on every social network: One user posts about their identity crisis and hundreds of others chime in with messages of support, consolation and profanity. In the ...

Clawdbot rebrands to Moltbot after trademark challenge Moltbot automates tasks via messaging platforms locally Security concerns surface as AI agent gains traction ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Over the past few days, a new AI viral sensation exploded across tech feeds, pulled Mac ...

You’re gonna love me for this. Say you’re calling customer service because you need help. Maybe your bill is wrong, your service is down or you want a refund. Instead of a person, a cheerful AI voice ...

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...